Key result
A PET-guided approach for consolidative radiotherapy in primary mediastinal large B-cell lymphoma yielded similar 5-year time to progression compared to the routine RT era (81% vs 78%, P=0.74).
Why the study?
The outcomes of primary mediastinal large B-cell lymphoma patients treated with chemoimmunotherapy in the rituximab era and the impact of a PET-adapted approach needed to be reviewed.
Does a PET-guided approach to consolidative radiotherapy maintain outcomes compared to universal radiotherapy in patients with primary mediastinal large B-cell lymphoma?
Population
159 patients >16 years of age with newly diagnosed PMBCL treated with chemotherapy + rituximab
Comparison
PET-guided radiotherapy approach (PET era) vs default consolidative radiotherapy (RT era)
Design
Retrospective database cohort study
Follow-up
Median 7.9 y
Authors
Loading...
May support PET-guided RT omission in PMBCL; leaves open need for prospective validation.
Cohort (n=159)
Does a PET-guided approach to consolidative radiotherapy maintain outcomes compared to universal radiotherapy in patients with primary mediastinal large B-cell lymphoma?
Absolute Event Rate: 81% vs 78%
p-value: p=0.74
A PET-guided approach for consolidative radiotherapy in PMBCL maintains high rates of time to progression and overall survival while sparing many patients from radiation.
Hayden et al. (2019) conducted a cohort in Primary mediastinal large B-cell lymphoma (PMBCL) (n=159). PET-guided approach vs. Routine consolidative radiotherapy approach (RT era) was evaluated on 5-year time to progression (TTP) (p=0.74). A PET-guided approach for consolidative radiotherapy in primary mediastinal large B-cell lymphoma yielded similar 5-year time to progression compared to the routine RT era (81% vs 78%, P=0.74).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: